TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
News|Slideshows|May 16, 2025
ACOG 2025: Poster Highlights for Primary Care
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
Details on 12 key abstracts with clinical relevance for primary care, from menopause management to PPD screening and HPV testing.
Advertisement
The American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical and Scientific Meeting in Minneapolis will showcase a range of research with clear implications for primary care. The editors of Patient Care combed through 280 abstracts selected for poster presentations and found 12 that standout—spanning menopause symptom management, adolescent menstrual care, postpartum depression, HPV screening, and more—for offering timely insights for frontline clinicians. Scroll through the slides above for insights on emerging pharmacologic treatments, novel screening strategies, and more.
Advertisement
Related to this article
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
In a pilot study of 20 midlife women with vasomotor symptoms, an AI-enabled VR program delivering CBT showed early feasibility and acceptability.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
2
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
3
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
4
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
5